Last update Oct. 9, 2016

Ropinirole Hydrochloride

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Non-ergotamine and D2 /D3 Dopamine agonist drug.
Indicated for Parkinson's disease and Restless Legs Syndrome (Evening dose).

At latest update no published data on excretion into breast milk were found.
Pharmacokinetic data do not allow easily predict the possibility of excretion into breastmilk, since a low protein-binding capacity would not prevent it, however, a large distribution volume would make it unlikely.
Its low oral bioavailability which decreases even more when taken with meals, suggests that plasma concentration would reach a very low level in the infant, except during the neonatal period and in case of prematurity in which intestinal absorption may be increased.
Side effects are neither frequent nor severe.

Prolactin levels may be lowered with decreased production of breastmilk during the first weeks after birth.
Gut absorption may be increased with higher plasma levels if taken together with Ciprofloxacin (Kaye 2000).

Whenever it is used while breastfeeding, it would be wise avoiding it during the first 15 to 20 days and assess milk production and onset of nausea, drowsiness or irritability in infants.
By waiting six hours after medication, excretion into breastmilk would possibly be lowered.

Alternatives

We do not have alternatives for Ropinirole Hydrochloride.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ropinirole Hydrochloride in other languages or writings:

Group

Ropinirole Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ropinirole Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 (36 - 57) %
Molecular weight 297 daltons
Protein Binding 10 - 40 %
VD 6,7 l/Kg
Tmax 1,5 hours
T1/2 6 hours

References

  1. GSK. Ropinirole. Drug Summary. 2014 Full text (in our servers)
  2. AEMPS. Ropinirol. Ficha técnica. 2011 Full text (in our servers)
  3. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf. 2010 Abstract
  4. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Abstract
  5. de Mey C, Enterling D, Meineke I, Yeulet S. Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Abstract
  6. de Mey C, Enterling D, Meineke I, Brendel E. Effects of the novel D2-dopaminergic agonist ropinirol on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers. Arzneimittelforschung. 1990 Abstract
  7. Acton G, Broom C. A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1989 Abstract

Total visits

2,469

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM